Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
                
Learn More
Learn More
                                    IL-18 R beta/IL-1 R7/ACPL Antibody (033), mFluor Violet 610 SE, Novus Biologicals™
 
                                    
                                    
                                    
                                    
                                
                            
                            
                            
                            
Rabbit Monoclonal Antibody
Supplier: Novus Biologicals NBP289315MFV610
Description
IL-18 R beta/IL-1 R7/ACPL Monoclonal antibody specifically detects IL-18 R beta/IL-1 R7/ACPL in Human samples. It is validated for ELISA, ELISASpecifications
| IL-18 R beta/IL-1 R7/ACPL | |
| Monoclonal | |
| mFluor Violet 610 SE | |
| 50mM Sodium Borate | |
| Rabbit | |
| Protein A purified | |
| RUO | |
| Primary | |
| Human | |
| Purified | 
| ELISA, Sandwich ELISA | |
| 033 | |
| ELISA, Sandwich ELISA Capture | |
| Accessory protein-like, ACPL, CD218 antigen-like family member B, CD218b, CD218b antigen, CDw218b, IL-18 receptor accessory protein, IL-18 receptor beta, IL-18RAcP, IL18RB, IL-18Rbeta, IL-18R-beta, IL-1R accessory protein-like, IL1R7, IL-1R7, IL-1R-7, IL-1RAcPL, interleukin 18 receptor accessory protein, Interleukin-1 receptor 7, interleukin-18 receptor accessory protein, Interleukin-18 receptor accessory protein-like, Interleukin-18 receptor beta, MGC120589, MGC120590 | |
| This antibody was obtained from a rabbit immunized with purified, recombinant Human IL-18 R beta/IL-1 R7/ACPL (Accession#: NP_003844.1; Met1-Gly357). | |
| 0.1 mL | |
| CD Markers | |
| 8807 | |
| Store at 4C in the dark. | |
| IgG | 
                    Product Content Correction
                
                Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
			
            Spot an opportunity for improvement?Share a Content Correction
            